TABLE 2.
Patient Cohort Characteristics for Studies Included in the Meta-analysis
| Pathologist diagnosis, n (%) | Segment length category, n (%) or cm, median (IQR) | |||||||
|---|---|---|---|---|---|---|---|---|
| First author (study number) | Study design | No. patients | Progressors | Non-progressors | Sex—male, n (%) | Age (y) | Progressors | Non-progressors |
| Critchley-Thorne et al18 (1)† | Nested case-control | Progressors: 38 Non-progressors: 145 |
NDBE=31 (81.6) IND=2 (5.3) LGD=5 (13.2) |
NDBE=138 (95.2) IND=2 (1.4) LGD=5 (3.4) |
Progressors: 33 (86.8) Non-progressors: 114 (78.6) |
Progressors: Mean: 60.1 +/- SD: 11.3 Non-progressors: Mean: 61.0 +/- SD: 12.1 |
Short=10 (26.3) Long=27 (71.1)Unknown=1 (2.6) |
Short=58 (40.0) Long=73 (50.3) Unknown=14 (9.7) |
| Critchley-Thorne et al19 (2)† | Nested case-control | Progressors: 30 Non-progressors: 145 |
NDBE=13 (43.3) IND=1 (3.3) LGD=16 (53.3) |
NDBE=138 (95.2) IND=2 (1.4) LGD=5 (3.4) |
Progressors: 28 (93.3) Non-progressors: 114 (78.6) |
Progressors: Mean: 61.8 +/- SD: 9.5 Non-progressors: Mean: 61.0 +/- SD: 12.1 |
Short=9 (30.0) Long=19 (63.3)Unknown=2 (6.7) |
Short=58 (40.0) Long=73 (50.3) Unknown=14 (9.7) |
| Davison et al20 (3) | Nested case-control | Progressors: 58 Non-progressors: 210 |
NDBE=43 (74.1) IND=5 (8.6) LGD=10 (17.2) |
NDBE=184 (87.6) IND=18 (8.6) LGD=8 (3.8) |
Progressors: 52 (89.7) Non-progressors: 152 (72.4) |
Progressors: Median: 63.8 IQR: 57-69.1 Non-progressors: Median: 60.8 IQR: 52.6-68 |
Short=17 (29.3) Long=38 (65.5)Unknown=3 (5.2) |
Short=92 (43.8) Long=113 (53.8)Unknown=5 (2.4) |
| Frei et al21 (4)‡ | Nested case-control | Progressors: 38 Non-progressors: 38 |
NDBE=38 (100) IND=0 (0) LGD=0 (0) |
NDBE=38 (100) IND=0 (0) LGD=0 (0) |
Progressors: 31 (82) Non-progressors: 27 (71) |
Progressors: Median: 64 IQR: 57-71 Non-progressors: Median: 62 IQR: 53-71 |
Median: 7 IQR: 5-8 |
Median: 6 IQR: 5-8 |
| Frei et al22 (5)§ | Retrospective cohort study | Progressors: 34 Non-progressors: 121 |
NDBE=0 (0) IND=0 (0) LGD*,§=34 (100) |
NDBE=0 (0) IND=0 (0) LGD*,§=121 (100) |
Progressors: 29 (85) Non-progressors: 94 (78) |
Progressors: Mean: 64 +/- SD: 9 Non-progressors: Mean: 61 +/- SD: 11 |
Median: 5 IQR: 3-7 |
Median: 4 IQR: 3-5 |
| Khoshiwal et al24 (6)§ | Retrospective cohort study | Progressors: 24 Non-progressors: 130 |
NDBE=9 (36.8) IND/LGD=15 (63.2) |
NDBE=96 (73.5) IND/LGD=34 (26.5) |
Progressors: 20 (83.3) Non-progressors: 102 (78.5) |
Progressors: Mean: 63.5 +/- SD: 9.5 Non-progressors: Mean: 61.0 +/- SD: 10.4 |
Median: 5.0 IQR: 3.0-6.3 |
Median: 4.0 IQR: 3.0-5.5 |
| Totals∥ | Progressors: 185 Non-progressors: 514 Total patients: 699 |
NDBE = 134 (71.3) IND/LGD = 54 (28.7) |
NDBE=456 (87.2) IND/LGD=67 (12.8) |
|||||
| Progressors and non-progressors: NDBE = 590 (83.0) IND/LGD = 121 (17.0) |
||||||||
Community-based diagnosis.
Study 1 and 2 utilized the same set of non-progressor patients as described in the Critchley-Thorne et al, 201719 study publication.
Study 4 included evaluation of additional spatial and temporal biopsies from 13 progressors that were also evaluated in study 1.
Study 5 and 6 evaluated the same cohort of patients (except for 1 patient), but progression outcomes were determined at different time points and diagnoses were provided by different pathologists.
Total number of progressors/non-progressors and total patients includes only unique patients. Totals for NDBE and IND/LGD include all patients.
NDBE indicates non-dysplastic Barrett’s esophagus; IND, indefinite for dysplasia; LGD, low-grade dysplasia; IQR, interquartile range; SD, standard deviation.